Clinical predictors of long-term efficacy of first-line pembrolizumab monotherapy in non-small cell lung cancer (NSCLC): an interim analysis of real-world dataHelen-Cara Younan, Debra H. Josephs, María Luisa Lazo de la Vega Monroy et al.|Lung Cancer|2022Cited by 0